GC Pharma (Formerly known as Green Cross)

52 articles about GC Pharma (Formerly known as Green Cross)

• GC Biopharma Reports Q1 2022 Results

  5/3/2022

  GC Biopharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 31 March 2022.

• GC Signs Definitive Agreement to Acquire US CDMO BioCentriq, Enhancing Global Capabilities

  4/19/2022

  GC corp. announced that it has signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc., a pioneering US-based contract development and manufacturing organization that designs and develops scalable cell and gene technologies.

• GC Pharma Changes Its Name to “GC Biopharma”

  3/29/2022

  GC Pharma announced that it has completed its corporate brand name change to GC Biopharma to solidify its identity as a biopharmaceutical company in the global healthcare industry.

• 

  COVID-19 Update: Impact of Asthma, Paxlovid Faces Production Issues

  3/14/2022

  A new study out of Duke University added weight to the determination that asthma in children did not increase infection risk, children slow to get COVID vaccine and more COVID-19 news.

• CORRECTING and REPLACING GC Pharma Receives Complete Response Letter From the U.S. FDA For 'GC5107'

  3/1/2022

  GC Pharma announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration in response to its Biologics License Application for ‘GC5107’.

• GC Pharma Receives Complete Response Letter From the U.S. FDA For 'ALYGLO'

  2/28/2022

  GC Pharma announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration in response to its Biologics License Application for ‘ALYGLO, 10% Liquid)’.

• GC Pharma Reports Full Year 2021 Results

  2/14/2022

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the year ended 31 December 2021.

• GC Pharma Reports Q3 2021 Results

  11/1/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 1 November 2021.

• GC Pharma Announces EMA Grants Orphan Drug Designation to Hunterase ICV, The World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II Administered by ICV Injection

  11/1/2021

  GC Pharma announced that the European Medicines Agency granted orphan drug designation to Hunterase ICV ) for the treatment of mucopolysaccharidosis type II in the European Union.

• GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A

  8/12/2021

  GC Pharma announced the approval of GreenGene F [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with haemophilia A in China by the National Medical Products Administration.

• GC Pharma and Tottori University Enter Research Collaboration and License Agreement for Development of GM1 Gangliosidosis Chaperone Therapy

  8/2/2021

  GC Pharma and Tottori University announced a worldwide licensing and collaboration agreement for the orally administrable chaperone drug of GM1 gangliosidosis.

• GC Pharma Reports Q2 2021 Results

  8/2/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 30 June 2021.

• US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

  5/5/2021

  GC Pharma announced that the United States Food and Drug Administration accepted the company’s Biologics License Application for 'GC5107,10% Liquid)’ intended for the treatment of Primary Humoral Immunodeficiency, a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.

• GC Pharma Reports Q1 2021 Results

  4/29/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 31 March 2021.

• GC Pharma Finalises Agreement With Moderna and the Government of the Republic of Korea for COVID-19 Vaccines Distribution

  3/4/2021

  GC Pharma announced that it will support Moderna and the government of the Republic of Korea in the distribution of 40 million doses of COVID-19 Vaccine Moderna, Moderna’s vaccine candidate against COVID-19, to support South Korea’s aim of providing vaccines to the public in a timely manner, subject to necessary local regulatory approvals.

• GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

  2/26/2021

  GC Pharma announced that it had submitted its Biologics License Application for 'GC5107',10% Liquid) to the United States Food and Drug Administration.

• GC Pharma Reports Full Year 2020 Results

  2/9/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited financial results for the year ended 31 December 2019.

• GC Pharma Reports Q3 2020 Results

  11/2/2020

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for third quarter of 2020.

• GC Pharma Reports Q2 2020 Results

  7/30/2020

  GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for second quarter of 2020. Second-Quarter Reported Results (1) Key Figures (1) Q2 2020 Growth (2) Total revenues

• Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

  7/20/2020

  Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year